馬來(lái)酸桂哌齊特聯(lián)合倍他樂(lè)克對(duì)冠心病心絞痛患者血漿vWF、CEC的影響

賈美麗

【摘要】 目的：探討馬來(lái)酸桂哌齊特聯(lián)合倍他樂(lè)克對(duì)冠心病心絞痛患者血漿血管血友病因子（vWF）、循環(huán)內(nèi)皮細(xì)胞（CEC）的影響。方法：選取2018年8月-2019年6月本院收治的冠心病心絞痛患100例為研究對(duì)象，應(yīng)用信封法將其分為對(duì)照組與研究組，各50例。對(duì)照組患者應(yīng)用倍他樂(lè)克治療，研究組應(yīng)用馬來(lái)酸桂哌齊特聯(lián)合倍他樂(lè)克進(jìn)行治療。比較兩組患者血漿vWF、CEC、炎性因子水平及兩組臨床療效。結(jié)果：治療干預(yù)后，兩組血漿vWF、CEC水平均低于治療干預(yù)前，且研究組均低于對(duì)照組，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療干預(yù)后，兩組血清中CRP、TNF-α水平均低于治療干預(yù)前，且研究組均低于對(duì)照組，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）。研究組臨床總有效率為96.0%，明顯高于對(duì)照組的78.0%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論：在冠心病心絞痛患者的臨床治療過(guò)程中應(yīng)用馬來(lái)酸桂哌齊特聯(lián)合倍他樂(lè)克治療方案，可顯著提升臨床療效，同時(shí)可改善患者血漿中vWF、CEC水平，改善炎性因子水平，臨床應(yīng)用效果理想，可考慮普及。

【關(guān)鍵詞】 馬來(lái)酸桂哌齊特 倍他樂(lè)克 冠心病心絞痛 血漿vWF CEC

[Abstract] Objective： To investigate the effect of Cinepazide Maleate combined with Betaloc on plasma vWF and CEC in angina pectoris patients with coronary heart disease. Method： A total of 100 cases of coronary heart disease and angina pectoris admitted to our hospital from August 2018 to June 2019 were selected as the study objects， they were divided into control group and study group by envelope method， 50 cases in each group. Patients in the control group were treated with Betaloc， the team was treated with Cinepazide Maleate combined with Betaloc. Plasma levels of vWF， CEC， inflammatory factors and clinical efficacy of the two groups were compared. Result： After the treatment intervention， plasma vWF and CEC levels in both groups were lower than those before the treatment intervention， and the study group is lower than those the control group， the differences were statistically significant （P<0.05）. After the treatment intervention， serum levels of CRP and TNF-α in both groups were lower than those before the treatment intervention， and the study group is lower than those the control group， the differences were statistically significant （P<0.05）. The total clinical response rate of the study group was 96.0%， significantly higher than the control group of 78.0%， the difference was statistically significant （P<0.05）. Conclusion： In the clinical treatment of angina pectoris patients with coronary heart disease， the application of Cinepazide Maleate combined with Betaloc treatment scheme can significantly improve the clinical efficacy， and improve the plasma levels of vWF and CEC， and improve the level of inflammatory factors， the clinical application effect is ideal， it can be considered to be popular.[Key words] Cinepazide Maleate Betaloc Coronary heart disease angina pectoris Plasma vWF Circulating endothelial cellFirst-authors address： Jiamusi University， Jiamusi 154002， China

冠心病在全球范圍內(nèi)具有較高的死亡率，為臨床較為常見的心血管病變，其發(fā)病人群多為中老年群體，對(duì)患者的身心健康帶來(lái)嚴(yán)重威脅，也是造成中老年患者死亡的重要因素[1]。冠心病在我國(guó)的發(fā)病率約為5%，在人口老齡化的加劇下，患病人數(shù)也逐年遞增[2]。相關(guān)研究資料顯示，心腦血管病變跟血管內(nèi)皮細(xì)胞（VEC）的損傷存在一定的相關(guān)性，該研究領(lǐng)域已將血管內(nèi)皮細(xì)胞保護(hù)作為了研究重點(diǎn)[3]。冠心病其發(fā)病機(jī)制主要為脂質(zhì)代謝出現(xiàn)異常，導(dǎo)致冠狀動(dòng)脈內(nèi)膜出現(xiàn)脂質(zhì)沉積，使血管管腔出現(xiàn)狹窄、阻塞現(xiàn)象，影響血液正常循環(huán)，使心臟發(fā)生血、氧缺失，從而誘發(fā)心絞痛，心絞痛是冠心病的主要表現(xiàn)癥狀，若患者得不到積極治療，會(huì)引發(fā)急性心肌梗死甚至死亡[4]。因此該病的治療主要以藥物保守治療，重建冠狀動(dòng)脈血運(yùn)，改善心肌缺血[5]。……